Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the provision of pharmaceutical services. Its product candidate, Selonabant, is a small molecule antagonist of cannabinoid binding receptor type-1. The company was founded by Joseph F. Lawler on April 23, 2020 and is headquartered in Lakeway, TX.
相关临床试验
6
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2020
进行中（未招募）
2
33.3%
已完成
3
50.0%
招募中
1
16.7%
暂无批准数据
- Anebulo Pharmaceuticals has begun dosing participants in a Phase I trial of intravenous selonabant, targeting acute cannabis-induced toxicity with NIDA funding support. - The CB1 receptor competitive antagonist previously demonstrated efficacy in Phase II oral studies, nearly completely blocking THC's subjective effects in healthy adults. - The IV formulation specifically targets pediatric patients experiencing acute cannabis toxicity, addressing a serious unmet medical need with potentially life-threatening consequences. - FDA interactions have confirmed significant demand for pediatric cannabis toxicity treatments, with the agency suggesting close collaboration for development.
- A comprehensive pipeline analysis reveals over 5 companies developing novel treatments for Cannabis Use Disorder (CUD), with AEF0117 by Aelis Farma representing a promising new pharmacological class in clinical trials. - The CUD therapeutic landscape includes drugs across multiple development stages from discovery to Phase III, with various routes of administration including oral, intravenous, subcutaneous, parenteral, and topical formulations. - Key players such as Aelis Farma, Anebulo Pharmaceuticals, and Indivior are advancing promising products like AEF0117, ANEB-001, and INDV-5004 through different phases of clinical development. - The pipeline assessment highlights significant collaborative efforts, acquisition activities, and licensing agreements aimed at addressing the critical unmet medical needs in cannabis use disorder treatment.
